AIMD Ainos Dashboard

Amarillo Biosciences, Inc. (ABI) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. Our goal is to introduce novel products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal. We engage in the advancement of low-dose non-injectable interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjögren’s syndrome, hepatitis C virus (HCV) and influenza. ABI primarily operates through three divisions: Pharmaceutical, Medical and Consumer. The Pharmaceutical division leverages a proprietary library of over a hundred scientific and clinical data studies on various human and animal applications of low-dose interferon, for patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing an innovative, state-of-the-art technology to treat metabolism related diseases such as Type 1 and Type 2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize our unique liposomal delivery systems. ABI currently has offices in the United States and Taiwan.

Company profile

Ticker

AIMD, AMAR

Exchange

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Viatris • Bristol-Myers Squibb • Warner Chilcott ...

Former names

AMARILLO BIOSCIENCES INC

SEC CIK

0001014763

Corporate docs

Articles of Incorporation & Bylaws

IRS number

751974352

Press releases

Pro users get this 30m faster

Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan

14 Jun 21

SAN DIEGO, CA / ACCESSWIRE / June 14, 2021 / Ainos, Inc. ('we', 'our', or the 'Company'), (OTC:AIMD), entered into an exclusive agreement to serve as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen

Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges

24 May 21

SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Ainos, Inc., f/k/a Amarillo Biosciences, Inc. ("we", "our", or the "Company"), (OTC:AIMD), is pleased to announce that the Financial Industry

Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."

21 Apr 21

AMARILLO, TX / ACCESSWIRE / April 21, 2021 / Ainos, Inc., f/k/a Amarillo Biosciences, Inc. ("we" or the "Company"), (OTC:AMAR), a company engaged in the discovery and development of pharmaceutical and

Investment data

Data from SEC filings

Securities sold

Number of investors

Financial summary

Financial statements Chart AIMD financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Ainos earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	9.38K	9.38K	9.38K	9.38K	9.38K	9.38K
Cash burn (monthly)	4.29K	23.35K	174.04K	132.22K	39.83K	41.94K
Cash used (since last report)	11.96K	65.09K	485.17K	368.61K	111.03K	116.93K
Cash remaining	-2.58K	-55.71K	-475.8K	-359.23K	-101.65K	-107.55K
Runway (months of cash)	-0.6	-2.4	-2.7	-2.7	-2.6	-2.6

Beta Read what these cash burn values mean

Institutional ownership Q4 2020

AIMD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: abroad, academic, acquire, advantage, advertising, Advisor, alternative, Alternatively, amended, Amendment, Antigen, antitrust, appointed, approximately, arrangement, artificial, assist, attached, background, bacterial, BBA, begin, beneficial, Bernard, biotechnology, bookkeeping, Calculation, candidate, capacity, carefully, Cayman, CFR, characterized, chemically, choose, Chrystal, civil, classified, cleared, climate, Cohen, collection, collectively, commence, Companuy, compete, compliance, comply, compound, connection, consummated, consummation, contemplated, content, contract, convey, COO, copy, corrupt, Cosmetic, costly, Counsel, criminal, cultural, currency, custom, damage, degree, description, diagnostic, difficult, difficulty, digital, diminish, director, disruption, distance, diversion, duly, duration, embedded, employment, enacted, enforcement, entirety, environment, equivalence, Esq, ethical, evolving, exceed, exempt, EXH, exhibit, expansion, experienced, export, expose, exposed, fabrication, facility, Failure, feasible, fewer, foregoing, formal, Formation, formatting, gain, Geographic, geopolitical, greatly, growth, handling, helicobacter, hereto, Hung, HYPERLINK, iii, impairment, impede, improve, improved, Incentive, IND, index, individually, infection, infrastructure, injury, inspection, instance, intelligence, intense, Interactive, invention, investigational, John, judgment, judiciously, Junyong, kit, Label, labeling, labor, laboratory, Lan, language, Lawrence, Lee, legislative, likelihood, Lin, Linkbase, liquidity, Living, loan, local, location, long, Maggie, mailing, media, monetary, MPA, Mutual, nationalization, NDA, negative, negatively, newer, November, omitted, Option, orphan, ownership, Page, partially, path, pending, person, physical, PMA, pneumonia, POCT, political, precedent, preclinical, predecessor, predicate, premarket, prior, privacy, prohibiting, proposed, protection, pursuing, pylori, quickly, rapid, rare, recapitalization, recoup, reference, Registrant, registration, regularly, Release, rely, repatriation, reputation, rescinded, resident, resignation, resigned, resource, Restated, rigidity, risky, routine, satisfy, satisfying, scaling, Schema, scope, Secretary, selected, Settlement, Shelton, shorten, shorter, Similarly, situation, SMART, specific, specifically, Specimen, staffing, steadily, stockholder, storage, strain, strategic, Submission, subscription, succeed, successfully, superiority, support, synthesized, Taxonomy, term, terminated, terrorism, text, therapeutic, thereunto, threatened, timeframe, traditional, transaction, Trust, Trustee, Tsai, unanticipated, undergo, undersigned, Underwriter, Unfavorable, University, unpredictable, unreasonable, vaginal, vary, varying, Vice, Virginia, VOC, volatile, volume, Wang, war, West, wide, workforce, written, XBRL

Removed: ABI, accurate, administering, annual, anticipate, assessed, audit, avoidance, broad, budget, cardiovascular, carried, catastrophic, cGMP, challenging, cited, climbing, commensurate, comparability, conducting, controlling, COSO, criteria, dedicated, deficiency, delayed, demonstrating, detailed, detected, detrimental, Diabetic, diet, dietary, differential, discreet, dosage, East, emerge, employing, enrolling, ensuring, epidemic, estimate, estimated, eventual, exhausted, exhaustive, existence, explain, external, eye, factor, fairly, faster, finally, fiscal, forecast, function, GAAP, gateway, genetic, glucose, greenfield, healing, heart, hiring, history, hypoglycemic, identified, imply, incidence, inflation, intestinal, involve, issue, kidney, knowledge, leading, lessening, lifestyle, lifetime, liver, Maxisal, microvascular, million, minimize, misstatement, necessitate, nephropathy, nerve, neuropathy, obese, obesity, optimized, outpacing, Overview, overweight, packaging, pain, patient, people, pervasive, phase, poor, population, prediction, preparation, prevalence, prevalent, prevented, progressive, projected, promise, promulgation, proper, publication, Quarterly, receiving, recruitment, reduction, Reform, reliability, reliance, remain, response, rest, retaining, retinopathy, salary, satisfactory, secondary, segregation, short, show, size, small, stage, standardized, suffer, suffering, sufficient, sufficiently, susceptible, Taiwanese, timing, topping, training, transplant, treated, trend, trial, trillion, turn, undesirable, undue, upward, wasted, weaker, week, Western, worsening, wound

From filing 10-Q 2021 Q1